market access

News

Open Health merges with HEOR and market access firm Pharmeri...

Open Health has joined forces with health economics and outcomes research (HEOR) company Pharmerit International in a move that strengthens its existing market access capabilities.

News

FDA finally approves Sandoz's Neulasta biosimilar, but will ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta.

News

After four-year wait, patients in England finally get Vertex...

NHS England has signed an agreement with US pharma Vertex covering all the company’s licensed cystic fibrosis medicines, and any future uses for them.

News

MSF calls for J&J to cut price of TB medicine

The humanitarian medical organisation Medecins Sans Frontieres (MSF) has called on Johnson & Johnson to cut the price of its anti-tuberculosis medicine Sirturo (bedaquiline), to not mor

News

Lack of reimbursement an issue for digital health products, ...

Many healthcare companies still don’t see digital health companies as viable partners despite recent progress in the industry, according to a new survey.

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Merck and Co's cancer drug Keytruda to smash sales records b...

Merck & Co's Keytruda cancer immunotherapy is set to become the world's top-selling drug by annual revenue in 2023, smashing sales records set by AbbVie's inflammatory disease drug Humi

Open Health merges with HEOR and market access firm Pharmeri...

FDA finally approves Sandoz's Neulasta biosimilar, but will ...

After four-year wait, patients in England finally get Vertex...

MSF calls for J&J to cut price of TB medicine

Lack of reimbursement an issue for digital health products, ...

Merck and Co's cancer drug Keytruda to smash sales records b...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

market access

Editor's Picks